Parliamentary panel flags under-utilisation of allocations in Department of Pharmaceuticals schemes and highlights corrective measures
Parliamentary Standing Committee notes low fund utilisation in some Department of Pharmaceuticals schemes and the Department of Pharmaceuticals responds with tighter monitoring, forecasting, and stakeholder outreach.
- The committee observed under-utilisation of allocations in some schemes of the Department of Pharmaceuticals.
- The department has strengthened periodic monitoring through Project Management Agencies, claim forecasting, milestone-based releases, and improved Treasury Single Account and Public Financial Management System readiness.
- The department is organising workshops, outreach programmes, and stakeholder consultations to improve understanding of scheme guidelines, eligibility conditions, documentation, and claim procedures.
- The department is supporting faster regulatory approvals for Bulk Drugs and Medical Device Park related schemes.
The Department-related Parliamentary Standing Committee on Chemicals and Fertilizers has flagged under-utilisation of allocations in some schemes of the Department of Pharmaceuticals. The issue matters because pharmaceutical-industry support schemes affect domestic manufacturing capacity, supply-chain resilience, and the pace of industrial policy execution.
The Department of Pharmaceuticals says it has taken corrective measures to improve fund utilisation in production-linked incentive schemes, bulk drug parks, and related initiatives. The parliamentary observation did not extend to the schemes of the Department of Fertilizers or the Department of Chemicals & Petrochemicals.
What happened now
UPSC can test how parliamentary committees improve executive accountability, and it can ask why scheme design, claim processing, regulatory approvals, and fund-flow systems affect the utilisation of production-linked incentive and bulk drug park allocations.
Related dispatches
